-

Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2026 on Thursday, April 30, 2026, before the U.S. financial markets open.

Management will provide an update on the Company and discuss first quarter 2026 results as well as expectations for the future via conference call on Thursday, April 30, 2026 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event.

About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. For more information, please visit www.alnylam.com or follow Alnylam on X, LinkedIn, Facebook, Instagram, or YouTube.

Contacts

Alnylam Pharmaceuticals, Inc.
Christine Akinc
(Investors and Media)
617-682-4340

Josh Brodsky
(Investors)
617-551-8276

Industry:

Alnylam Pharmaceuticals, Inc.

NASDAQ:ALNY
Release Versions
English

Contacts

Alnylam Pharmaceuticals, Inc.
Christine Akinc
(Investors and Media)
617-682-4340

Josh Brodsky
(Investors)
617-551-8276

More News From Alnylam Pharmaceuticals, Inc.

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances across its growing neuroscience portfolio at the Alzheimer’s Association International Conference (AAIC) 2026. This scientific progress underscores the potential of RNAi therapeutics to address the needs of patients with debilitating neurological diseases. Mivelsiran: An investigational RNAi therapeutic targeting amyloid precursor protein (APP) in develop...

Alnylam to Host Tenth “RNAi Roundtable” Webcast Series

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 10th series of “RNAi Roundtable” webinars over the coming months. The series will offer presentations from Alnylam scientists and physicians who will review recent progress in a selection of the Company’s pipeline programs, as well as medical thought leaders who will provide their perspectives on unmet clinical needs. Each event will b...

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

CAMBRIDGE, Mass. & PALO ALTO, Calif.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Inceptive Nucleics, Inc., which builds foundation models of life, today announced a strategic collaboration agreement to increase the pace of therapeutic innovation. The collaboration is valued at up to $2B with upfront consideration of $30M, including cash and the purchase of Inceptive equity. Inceptive is eligible to receive additional payments based...
Back to Newsroom